基于人乳头瘤病毒次要衣壳蛋白L2的广谱疫苗研究进展

Research Progress in Minor Capsid Protein L2-based Pan-HPV Vaccine

人乳头瘤病毒(Human papillomavirus,HPV)次要衣壳蛋白L2具有广谱中和表位,被认为具有成为新一代广谱预防性疫苗的潜力。目前上市的HPV疫苗均是基于主要衣壳蛋白L1,但都被证明只对疫苗保护型别有效,仍无法覆盖所有高危型别的HPV,且成本较高不利于在发展中国家推广,因此急需开发低成本高覆盖的预防性疫苗。本文综述了基于L2疫苗的相关研究策略,对HPV广谱预防性疫苗的研究具有参考意义。

Human papilloma virus(HPV)minor capsid protein L2 contains cross ‐ neutralizing epitopes and is considered to be a potential candidate for the next generation vaccine.Currently,all the licensed HPV vaccines are based on the HPV major capsid protein L1.Nevertheless,the vaccine still cannot protect against the infection of all the high‐risk HPV types as it only conferred homogeneous protection in clinical trials.As a result,it is necessary to develop a cost ‐ effective and broad coverage prophylactic vaccine.This review focuses on those strategies to improve the immunogenicity of L2 protein for broad neutralization,which will benefit the research of pan‐HPV prophylactic vaccine.